nav-left cat-right
cat-right

Controlled Release Conference, 20th – 21st A...

As controlled release drug delivery systems continue to play an important role among the emerging areas of research in the treatment of diseases, this event will focus on specific topics looking at advances made in the field and how to overcome the challenges involved when developing controlled release formulations. Returning for its twelfth year and following on from the major success of previous events, SMi are proud to...

Experimental drug could thwart measles outbreaks

A new antiviral drug may provide an effective way to treat measles in those who have not been vaccinated. When tested in an oral form in animals infected with a similar version of the measles virus, the experimental drug not only prevented animals from dying of the disease, but it significantly reduced virus levels. Developed by scientists from the Institute for Biomedical Sciences at Georgia State University, the Emory...

Toward Drug Repurposing in Epigenetics

DNA hypomethylating drugs that act on DNA methyltransferase (DNMT) isoforms are promising anticancer agents. By using a well-characterized live-cell system to measure DNA methylation revisions (imprints), we characterize olsalazine, an approved anti-inflammatory drug, as a novel DNA hypomethylating agent. The cell-based screen used in this work is highly tractable, internally controlled, and well-suited for a drug repurposing...

Study: R&D for neglected diseases still negli...

Despite some high-profile commitments from some of the industry’s largest innovators, R&D for some of the world’s most deadly neglected diseases remains underfunded and unimpressive, according to a study, a state of affairs that has barely improved over the last three decades. Of the 336 new chemical entities approved around the world from 2000 to 2011, only 1% were for neglected diseases, according to a...

Research at A&M and Scripps finds HIV-killing...

COLLEGE STATION – A powerful topical preventative for HIV, the virus that causes AIDS, could be a step closer to clinical trials, thanks to a newly discovered molecular compound that research at Texas A&M University and the Scripps Research Institute shows dissolves the virus on contact. The ability of the synthetic compound known as “PD 404,182” to break apart the AIDS-causing virus before it can...

First Clinical Trial of Autologous Cardiac Stem Ce...

Initial data from the first ever trial to evaluate autologous cardiac stem cell (CSC) transplants in humans suggests that the treatment improves left ventricular (LV) systolic function by an average of 12% over one year, and reduces infarct size in patients with severe heart failure due to ischemic heart disease. The trial investigators say the results triple the 4% average improvement that they had projected and calls...
Page 1 of 512345